Forest Laboratories — Proxy Contest (August 2011)
8 slides from Forest Laboratories's proxy contest presentation, Aug 4, 2011
Slide 1: Icahn's August 3rd Claims Are Filled With Misrepresentations
Forest Labs Icahn's August 3rd Claims Are Filled With Misrepresentations August 4, 2011
Slide 2: In His August 3rd Filing, Icahn...
In His August 3rd Filing, Icahn: Asks Forest shareholders to ignore Denner's and Mulligan's obvious board conflicts Presents misleading conflict of interest data about Forest and other companies Uses misleading Forest share price performance data by selecting a completely arbitrary time frame and by
Slide 3: Denner and Mulligan Are Conflicted
Denner and Mulligan Are Conflicted Icahn doesn't challenge the fact that Biogen Idec and Amylin compete with Forest in important therapeutic areas Biogen Idec website: "We are interested in partnerships in our core therapeutic areas of neurology and other areas of high unmet need. In addition, we we
Slide 4: Icahn Misrepresents Conflict of Interest Data
Icahn Misrepresents Conflict of Interest Data Icahn erroneously states that Forest has no guidelines on "unacceptable conflicts." We believe that ALL conflicts are unacceptable Our guidelines regarding conflicts are clear and available on our website: "No Director shall serve as a director, officer
Slide 5: Icahn's Share Price Performance Data is Misleading
Icahn's Share Price Performance Data is Misleading Forest has presented consistent data demonstrating short- and long-term outperformance against both the S&P 500 and the AMEX Pharmaceutical Index (DRG) In contrast, Icahn: Opportunistically selects 7-year performance data and excludes the most recen
Slide 6: We have outperformed the most relevant indices - the S&P and the DRG
We have outperformed the most relevant indices - the S&P 500 and the DRG - over both the short-term and long-term Icahn Unfairly Criticizes our Share Price Performance Notes The AMEX Pharmaceutical Index (DRG) was developed on July 31, 1991 Price performance does not include dividends Price Performa
Slide 7: Research Analysts Respect Forest's Accomplishments
Research Analysts Respect Forest's Accomplishments Icahn has endorsed a research analyst who is an outlier with a long-held, consistently negative view of the Company. Most other Forest sell-side analysts disagree: Corey Davis, Jefferies Research, 5/16/11: "Best late stage pipeline in all biopharma
Slide 8: Important Additional Information
Important Additional Information Forward Looking Information Except for the historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertaint